human tim3 biotinylated antibody  (R&D Systems)

Journal: Cell stem cell

Article Title: Synthetic immune checkpoint engagers protect HLA-deficient iPSCs and derivatives from innate immune cell cytotoxicity.

doi: 10.1016/j.stem.2023.10.003

Figure Lengend Snippet: Figure 1. Synthetic immune cell checkpoint engagers (A) The use of the immune cell receptors LILRB1, LILRB3, TIM3, PD-1, and SIRPa for the protection of cell therapeutics against innate immune cell killing comes with different challenges related to their natural ligands. (B and C) The expression of LILRB1, LILRB3, TIM3, PD-1, and SIRPa on primary human NK cells and macrophages is shown (representative flow cytometry histograms, B; mean ± SD, n = 5, C). The percentage of positive cells is presented. (D) Synthetic immune cell checkpoint engagers with agonistic function were designed for LILRB1, LILRB3, TIM3, PD-1, and SIRPa. All engagers have specific binding domains for the immune cell receptors, are membrane-bound, and lack intracellular domains.

Article Snippet: CDJ-H82F7, AcroBiosystems), biotinylated human TIM3 protein with Avitag (Cat.no.

Techniques: Expressing, Cytometry, Binding Assay, Membrane

Journal: Oncoimmunology

Article Title: Identification and characterization of M6903, an antagonistic anti–TIM-3 monoclonal antibody

doi: 10.1080/2162402X.2020.1744921

Figure Lengend Snippet: M6903 bound to human and non-human primate TIM-3, but not to mouse or rat TIM-3. Kinetic constants for binding of M6903 to orthologues of TIM-3 were determined by SPR using a Langmuir 1:1 binding model for human, cynomolgus, marmoset, and mouse, and the equilibrium binding constant was derived from the ratio of the kinetic constants. Rat TIM-3 was tested by ELISA. Mouse and rat TIM-3 were measured using pre-optimized versions of the antibodies with identical variable region sequence and IgG1 allotype. “No binding” indicates values were not above background. Constants shown are the average of two measurements.

Article Snippet: In addition to these T cell markers, PBMCs were also incubated with a 1 μg biotinylated anti-HEL IgG1 control (EMD Serono, A11-122-3 labeled in-house), biotinylated anti-LAG (EMD Serono, 4290D11, labeled in-house), or biotinylated anti-TIM-3 IgG1 antibody (produced in transiently transfected HEK293 cells, EMD Serono, 3903E11 (VH1.2-VL1.3) labeled in-house) for 45 minutes, followed by streptavidin-APC (eBioscience, 17–431782) for 30 minutes.

Techniques: Binding Assay, Derivative Assay, Enzyme-linked Immunosorbent Assay, Sequencing